Coccidioidomycosis Clinical Trial
Official title:
Improving the Appearance of Skin and Hair in Patients Undergoing Valley Fever Treatment
This will be a multi-visit study that will take approximately 3 hours in total. Up to 200 subjects from the BUMC Valley Fever and BUMC Dermatology clinics will be enrolled in this study and assigned to one of three cohorts according to timeline of oral anti-fungal therapy. Subjects in Cohort 1 will be randomized to apply topical cholesterol-containing moisturizers to the skin, hair and lips on either the right or left side of the body daily. Measurements of skin barrier function, appearance of skin and hair, and hair samples will be obtained at baseline and at 4 week follow-up visits. Cohorts 2 and 3 will be observational groups at differing points in oral antifungal treatment regimen. Subjects will be randomized to have measurements of skin barrier function and hair and skin characteristics obtained from either the right or left side of the body at baseline and at monthly follow-up visits.
Coccidioidomycosis, also known as Valley Fever, is a fungal condition most commonly seen in Arizona and can affect multiple organs, including the skin, lung, bone, joints, and central nervous system. Oral antifungal therapy such as fluconazole is the first-line medication to treat coccidioidomycosis. Through the investigator's clinical observations at the Valley Fever Center for Excellence, nearly all patients who have been placed on systemic azole treatment show some extent of cosmetic changes in their skin and hair, such as dry skin, chapped lips, hair loss, and change in hair characteristics. The goals of the study are to 1) understand the cosmetic changes in the skin and hair in patients initiating and discontinuing long-term oral antifungals, and 2) to examine whether cholesterol-based commercially-available moisturizers for the skin and for the hair can improve the cosmetic appearance better than a vehicle without these cholesterol ingredients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04208321 -
Safety and Pharmacokinetics of VT-1598
|
Phase 1 | |
| Terminated |
NCT00614666 -
Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02190266 -
Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis
|
||
| Completed |
NCT00796809 -
Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis
|
N/A | |
| Withdrawn |
NCT02908334 -
Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis
|
Phase 2 | |
| Completed |
NCT00423267 -
POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)
|
Phase 3 | |
| Completed |
NCT00690092 -
A Multi-center Study of Spherule-Derived Coccidioidin
|
Phase 3 | |
| Withdrawn |
NCT04809649 -
SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole
|
Phase 2 | |
| Completed |
NCT03908632 -
An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged > / = 14 Years Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC)
|
||
| Terminated |
NCT02663674 -
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
|
Phase 4 | |
| Completed |
NCT03059992 -
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
|
Phase 3 | |
| Completed |
NCT00002325 -
A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common
|
N/A |